NCT01646450View on ClinicalTrials.gov

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Icotinib

Icotinib: 125mg, oral administration, three times per day.

Trial Locations (1)

200030

Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity, Shanghai

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY